News

Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

1 February 2024

Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces initiation of coverage by EuroLand Corporate.

In a study entitled L’imagerie cellulaire à la loupe, EuroLand Corporate recommends Mauna Kea shares to Buy, with a target price of €0.71, representing an increase of +56% compared with the share’s closing price on January 31, 2024 (€0.456).

This new study adds to the consensus of financial analysts who already covers the stock alongside Portzamparc and Gilbert Dupont.

Latest News

Publication of the 2024 Annual Financial Report 

Publication of the 2024 Annual Financial Report 

Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 

Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update